XOMA (XOMA) Investor Presentation - Slideshow

Company Overview - XOMA has a portfolio of over 70 assets across more than 30 disclosed indications[8] - XOMA focuses on acquiring drug royalties associated with mid- to early-stage clinical candidates, particularly those with blockbuster potential licensed to large-cap partners[8] - XOMA's royalty interests are not diluted as companies raise capital[8] Portfolio Advancements and Key Assets - Since 2017, XOMA's portfolio has seen over 25 advancements from phase to phase[13] - Roche's faricimab, in which XOMA holds a 0.5% royalty, has been approved by the FDA for the treatment of nAMD and DME[16, 49] - Key portfolio assets include NIS793 (Novartis), iscalimab (Novartis), MK-4830 (Merck), osocimab (Bayer), and cetrelimab (Janssen), with royalty rates ranging from low single-digit to low teens percentages[16] Financial and Operational Highlights - XOMA acquired economic interest in Roche's faricimab from Affitech for $6 million upfront[38] - XOMA earned a $35 million milestone from Novartis with the first patient dosed in the NIS793 Phase 3 mPDAC study[38] - XOMA has over $1 billion in potential milestones across its portfolio[52, 60, 63, 66]